Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Jul 10;8(7):e68152.
doi: 10.1371/journal.pone.0068152. Print 2013.

Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis

Huw Price  1 , David Dunn, Deenan Pillay, Firouze Bani-Sadr, Theodora de Vries-Sluijs, Mamta K Jain, Noriyoshi Kuzushita, Stefan Mauss, Marina Núñez, Reto Nüesch, Marion Peters, Thomas Reiberger, Christoph Stephan, Lionel Tan, Richard Gilson
Affiliations
Meta-Analysis

Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis

Huw Price et al. PLoS One. .

Abstract

Background: Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent and the one with the lowest risk of resistance appears to be tenofovir (TDF). However there are several questions that remain unanswered regarding the use of TDF, including the proportion of patients that achieves suppression of HBV viral load and over what time, whether suppression is durable and whether prior treatment with other HBV-active drugs such as lamivudine, compromises the efficacy of TDF due to possible selection of resistant HBV strains.

Methods: A systematic review and meta-analysis following PRISMA guidelines and using multilevel mixed effects logistic regression, stratified by prior and/or concomitant use of lamivudine and/or emtricitabine.

Results: Data was available from 23 studies including 550 HBV/HIV coinfected patients treated with TDF. Follow up was for up to seven years but to ensure sufficient power the data analyses were limited to three years. The overall proportion achieving suppression of HBV replication was 57.4%, 79.0% and 85.6% at one, two and three years, respectively. No effect of prior or concomitant 3TC/FTC was shown. Virological rebound on TDF treatment was rare.

Interpretation: TDF suppresses HBV to undetectable levels in the majority of HBV/HIV coinfected patients with the proportion fully suppressed continuing to increase during continuous treatment. Prior treatment with 3TC/FTC does not compromise efficacy of TDF treatment. The use of combination treatment with 3TC/FTC offers no significant benefit over TDF alone.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Summary of study search and inclusion (PRISMA flow diagram).
Figure 2
Figure 2. Forest plots of study arms included in the meta-analysis at years 1–3.
Figure 3
Figure 3. Log of HBV viral load assay cut-off against proportion undetectable at one year.
Figure 4
Figure 4. Percentage with undetectable HBV viral load over time, by HBeAg status.
Figure 5
Figure 5. Funnel plot of standard error against proportion undetectable at one year – all study arms (with pseudo 95% confidence limits).
See this image and copyright information in PMC

References

    1. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, et al. (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166: 1632–1641. - PubMed
    1. Brook G, Main J, Nelson M, Bhagani S, Wilkins E, et al. (2010) British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 11: 1–30. - PubMed
    1. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, et al. (2010) Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 139: 1218–1229. - PubMed
    1. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097. - PMC - PubMed
    1. Avihingsanon A, Lewin SR, Kerr S, Chang JJ, Piyawat K, et al. (2010) Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antivir Ther 15: 917–922. - PubMed

Publication types

MeSH terms